## Michele Cicala

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4966915/publications.pdf

Version: 2024-02-01

57758 98798 5,234 155 44 67 citations h-index g-index papers 165 165 165 4988 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Association between postâ€reflux swallowâ€rnduced peristaltic wave index and esophageal mucosal integrity in patients with GERD symptoms. Neurogastroenterology and Motility, 2023, 35, e14344.	3.0	4
2	Relevance of Excessive Air Swallowing in GERD Patients With Concomitant Functional Dyspepsia and Poor Response to PPI Therapy. Journal of Clinical Gastroenterology, 2023, 57, 466-471.	2.2	2
3	Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. Journal of Dermatological Treatment, 2022, 33, 1279-1286.	2.2	7
4	Reflux characteristics triggering postâ€reflux swallowâ€induced peristaltic wave (PSPW) in patients with GERD symptoms. Neurogastroenterology and Motility, 2022, 34, e14183.	3.0	10
5	Normal values and regional differences in oesophageal impedance-pH metrics: a consensus analysis of impedance-pH studies from around the world. Gut, 2021, 70, 1441-1449.	12.1	49
6	Safety and tolerability of a novel oral nutritional supplement in healthy volunteers. Clinical Nutrition, 2021, 40, 946-955.	5.0	4
7	Postreflux swallowâ€induced peristaltic wave index from pHâ€impedance monitoring associates with esophageal body motility and esophageal acid burden. Neurogastroenterology and Motility, 2021, 33, e13973.	3.0	14
8	Esophageal pH increments associated with postâ€reflux swallowâ€induced peristaltic waves show the occurrence and relevance of esophagoâ€salivary reflex in clinical setting. Neurogastroenterology and Motility, 2021, 33, e14085.	3.0	20
9	Association between Dietary Habits and Fecal Microbiota Composition in Irritable Bowel Syndrome Patients: A Pilot Study. Nutrients, 2021, 13, 1479.	4.1	15
10	Diarrhea Predominant-Irritable Bowel Syndrome (IBS-D): Effects of Different Nutritional Patterns on Intestinal Dysbiosis and Symptoms. Nutrients, 2021, 13, 1506.	4.1	48
11	Impaired Colonic Contractility and Intestinal Permeability in Symptomatic Uncomplicated Diverticular Disease. Journal of Neurogastroenterology and Motility, 2021, 27, 292-301.	2.4	6
12	Patients With Definite and Inconclusive Evidence of Reflux According to Lyon Consensus Display Similar Motility and Esophagogastric Junction Characteristics. Journal of Neurogastroenterology and Motility, 2021, 27, 565-573.	2.4	7
13	Sa153 ESOPHAGEAL PH INCREMENTS ASSOCIATED WITH POST-REFLUX SWALLOW-INDUCED PERISTALTIC WAVES SHOW THE OCCURRENCE AND RELEVANCE OF ESOPHAGO-SALIVARY REFLEX IN CLINICAL SETTING Gastroenterology, 2021, 160, S-440-S-441.	1.3	O
14	Novel impedanceâ€pH parameters are associated with proton pump inhibitor response in patients with inconclusive diagnosis of gastroâ€oesophageal reflux disease according to Lyon Consensus. Alimentary Pharmacology and Therapeutics, 2021, 54, 412-418.	3.7	42
15	The Results From Up-Front Esophageal Testing Predict Proton Pump Inhibitor Response in Patients With Chronic Cough. American Journal of Gastroenterology, 2021, 116, 2199-2206.	0.4	14
16	Editorial: inconclusive diagnosis of GERD: are new parameters in impedanceâ€pHmetry ready for clinical use? Authors' reply. Alimentary Pharmacology and Therapeutics, 2021, 54, 498-499.	3.7	2
17	Gut Microbiota and Related Electronic Multisensorial System Changes in Subjects With Symptomatic Uncomplicated Diverticular Disease Undergoing Rifaximin Therapy. Frontiers in Medicine, 2021, 8, 655474.	2.6	6
18	The impact of the intestinal microbiota and the mucosal permeability on three different antibiotic drugs. European Journal of Pharmaceutical Sciences, 2021, 164, 105869.	4.0	3

#	Article	IF	CITATIONS
19	Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict PPI response in GERD patients with extra esophageal symptoms. Digestive and Liver Disease, 2020, 52, 173-177.	0.9	22
20	Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients. Neurogastroenterology and Motility, 2020, 32, e13752.	3.0	27
21	Fragmented and failed swallows on esophageal highâ€resolution manometry associate with abnormal reflux burden better than weak swallows. Neurogastroenterology and Motility, 2020, 32, e13736.	3.0	32
22	Role of Overweight and Obesity in Gastrointestinal Disease. Nutrients, 2020, 12, 111.	4.1	59
23	Earlyâ€onset versus lateâ€onset Crohn's disease: An Italian cohort study. United European Gastroenterology Journal, 2020, 8, 52-58.	3.8	10
24	Understanding the relationship between esophageal motor disorders and reflux disease. Expert Review of Gastroenterology and Hepatology, 2020, 14, 933-940.	3.0	3
25	OC.03.3 RELEVANCE OF ESOPHAGEAL SHORTENING DURING INCOMPLETE TRANSIENT LES RELAXATIONS IN GERD PATHOGENESIS. Digestive and Liver Disease, 2020, 52, S12-S13.	0.9	О
26	TO4.01.2 WALL THICKNESS RATIO, A NEW MAGNETIC RESONANCE PARAMETER, PREDICTS THE OUTCOME OF BIOLOGICAL THERAPY IN PATIENTS WITH ILEAL AND ILEOCOLONIC CROHN'S DISEASE. Digestive and Liver Disease, 2020, 52, S117-S118.	0.9	0
27	T05.02.11 SERUM DIAMINOXIDASE LEVELS IN IRRITABLE BOWEL SYNDROME PATIENTS COMPARED TO HEALTHY CONTROLS. Digestive and Liver Disease, 2020, 52, S154-S155.	0.9	О
28	Palmitic Acid Affects Intestinal Epithelial Barrier Integrity and Permeability In Vitro. Antioxidants, 2020, 9, 417.	5.1	23
29	Clinical impact of proton pump inhibitor response and dependence. Neurogastroenterology and Motility, 2020, 32, e13846.	3.0	0
30	A SIGE-SINGEM-AIGO technical review on the clinical use of esophageal reflux monitoring. Digestive and Liver Disease, 2020, 52, 966-980.	0.9	27
31	High-resolution Manometry Determinants of Refractoriness of Reflux Symptoms to Proton Pump Inhibitor Therapy. Journal of Neurogastroenterology and Motility, 2020, 26, 447-454.	2.4	19
32	Nutritional Aspects in Inflammatory Bowel Diseases. Nutrients, 2020, 12, 372.	4.1	127
33	Mechanisms of Action of Prebiotics and Their Effects on Gastro-Intestinal Disorders in Adults. Nutrients, 2020, 12, 1037.	4.1	108
34	Fecal and Mucosal Microbiota Profiling in Irritable Bowel Syndrome and Inflammatory Bowel Disease. Frontiers in Microbiology, 2019, 10, 1655.	3.5	146
35	New classifications of gastroesophageal reflux disease: an improvement for patient management?. Expert Review of Gastroenterology and Hepatology, 2019, 13, 761-769.	3.0	11
36	How to select patients for antireflux surgery? The ICARUS guidelines (international consensus) Tj ETQq0 0 0 rgB1	「/Overlocl 12.1	k 10 Tf 50 67 80

#	Article	IF	CITATIONS
37	OC.16.5 REFLUX PATTERN AND ROLE OF IMPEDANCE-PH VARIABLES IN PREDICTING PPI RESPONSE IN PATIENTS WITH SUSPECTED REFLUX LARYNGITIS SYNDROME. Digestive and Liver Disease, 2019, 51, e123.	0.9	0
38	Tu1188 – Reflux Pattern and Role of Impedance-Ph Variables in Predicting Ppi Response in Patients with Suspected Reflux Laryngitis Syndrome. Gastroenterology, 2019, 156, S-977.	1.3	0
39	Sa1940 – Fecal and Mucosal Microbiota Profiling in Inflammatory Bowel Disease and Irritable Bowel Syndrome: A Focus on the Genetic Diversity of Akkermantia Muciniphila. Gastroenterology, 2019, 156, S-461.	1.3	O
40	Tu1180 – High Resolution Manometry (HRM) Evaluation of Patients with Gastro-Esophageal Reflux Disease (GERD) Symptoms Unresponsive to Proton Pump Inhibitor (PPI) Therapy. Gastroenterology, 2019, 156, S-974.	1.3	0
41	Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD). Digestive and Liver Disease, 2019, 51, 632-639.	0.9	36
42	Exploring the genetic diversity of the 16S rRNA gene of <i>Akkermansia muciniphila</i> in IBD and IBS. Future Microbiology, 2019, 14, 1497-1509.	2.0	15
43	Gut mucosal-associated microbiota better discloses inflammatory bowel disease differential patterns than faecal microbiota. Digestive and Liver Disease, 2019, 51, 648-656.	0.9	67
44	High-resolution Manometry Findings During Solid Swallows Correlate With Delayed Reflux Clearance and Acid Exposure Time in Non-erosive Reflux Disease Patients. Journal of Neurogastroenterology and Motility, 2019, 25, 68-74.	2.4	11
45	Effect of <i>Lactobacillus paracasei</i> CNCM Iâ€1572 on symptoms, gut microbiota, short chain fatty acids, and immune activation in patients with irritable bowel syndrome: A pilot randomized clinical trial. United European Gastroenterology Journal, 2018, 6, 604-613.	3.8	77
46	Impairment of GH/IGF-1 Axis in the Liver of Patients with HCV-Related Chronic Hepatitis. Hormone and Metabolic Research, 2018, 50, 145-151.	1.5	12
47	Role of Esophageal Motility, Acid Reflux, and of Acid Suppression in Nonobstructive Dysphagia. Journal of Clinical Gastroenterology, 2018, 52, 607-613.	2.2	4
48	Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in nonâ€erosive reflux disease. Alimentary Pharmacology and Therapeutics, 2018, 48, 1074-1081.	3.7	32
49	Sulles - Colonic Impairment of Intestinal Barrier Integrity Correlates with Symptoms in Diarrhea-Predominant Irritable Bowel Syndrome Patients. Gastroenterology, 2018, 154, S-500-S-501.	1.3	O
50	Intra-bolus pressure and esophagogastric gradient, assessed with high-resolution manometry, are associated with acid exposure and proximal migration of refluxate. Ecological Management and Restoration, 2018, 31, .	0.4	0
51	Su1660 - The Fecal Microbial Ecosystem in Irritable Bowel Syndrome is Distinct According to Bowel Habit Characteristics. Gastroenterology, 2018, 154, S-566.	1.3	O
52	Tu1924 - Dietary Concentrations of Palmitic Acid Affect Gut Epithelial Integrity. Gastroenterology, 2018, 154, S-1055.	1.3	0
53	OC.03.2 COLONIC IMPAIRMENT OF INTESTINAL BARRIER INTEGRITY CORRELATES WITH SYMPTOMS IN DIARRHEA-PREDOMINANT IRRITABLE BOWEL SYNDROME PATIENTS. Digestive and Liver Disease, 2018, 50, e74-e75.	0.9	O
54	259 - Type-1 Cannabinoid Receptor Effect on Human Colonic Motility in Patients with Slow Transit Constipation and Controls. Gastroenterology, 2018, 154, S-63.	1.3	0

#	Article	IF	CITATIONS
55	Fecal Clostridiales distribution and short hain fatty acids reflect bowel habits in irritable bowel syndrome. Environmental Microbiology, 2018, 20, 3201-3213.	3.8	59
56	Therapeutic Drug Monitoring is More Cost-Effective than a Clinically Based Approach in the Management of Loss of Response to Infliximab in Inflammatory Bowel Disease: An Observational Multicentre Study. Journal of Crohn's and Colitis, 2018, 12, 1079-1088.	1.3	50
57	Sul 103 - Correlation Between Peristaltic Function and Mucosal Integrity in Gerd Patients. Gastroenterology, 2018, 154, S-489.	1.3	O
58	Nutritional status and bioelectrical phase angle assessment in adult Crohn disease patients receiving anti-TNFα therapy. Digestive and Liver Disease, 2017, 49, 495-499.	0.9	22
59	Randomised clinical trial: mucosal protection combined with acid suppression in the treatment of nonâ€erosive reflux disease – efficacy of Esoxx, a hyaluronic acid–chondroitin sulphate based bioadhesive formulation. Alimentary Pharmacology and Therapeutics, 2017, 45, 631-642.	3.7	64
60	Response to Optimal PPI Therapy, Association with Atypical and Functional GI Symptoms in NERD Patients: Results from Nerone Study. Gastroenterology, 2017, 152, S3-S4.	1.3	0
61	Classification of esophageal motor findings in gastroâ€esophageal reflux disease: Conclusions from an international consensus group. Neurogastroenterology and Motility, 2017, 29, e13104.	3.0	158
62	Ambulatory reflux monitoring for diagnosis of gastroâ€esophageal reflux disease: Update of the Porto consensus and recommendations from an international consensus group. Neurogastroenterology and Motility, 2017, 29, 1-15.	3.0	275
63	Looking for the most Useful Taxa as Microbial Biomarkers to Decipher IBD Microbiota: A Pilot Study. Gastroenterology, 2017, 152, S626.	1.3	0
64	Increased Frequency of Air Swallows During 24 Hours in Nerd Patients non Responder to Proton Pump Inhibitors. Gastroenterology, 2017, 152, S661.	1.3	0
65	Esophageal High Resolution Manometry Variables in Gerd Patients, Responders and Non-Responders to Proton Pump Inhibitor Therapy. Gastroenterology, 2017, 152, S689-S690.	1.3	0
66	Supernatants of irritable bowel syndrome mucosal biopsies impair human colonic smooth muscle contractility. Neurogastroenterology and Motility, 2017, 29, e12928.	3.0	12
67	Effect of Inulin on Proteome Changes Induced by Pathogenic Lipopolysaccharide in Human Colon. PLoS ONE, 2017, 12, e0169481.	2.5	15
68	Role of Mixed Reflux and Hypomotility with Delayed Reflux Clearance in Patients with Non-cardiac Chest Pain. Journal of Neurogastroenterology and Motility, 2016, 22, 606-612.	2.4	14
69	Bloating is associated with worse quality of life, treatment satisfaction, and treatment responsiveness among patients with constipationâ€predominant irritable bowel syndrome and functional constipation. Neurogastroenterology and Motility, 2016, 28, 581-591.	3.0	30
70	Asymptomatic Parasitic Infection in a Crohn's Disease Patient on Anti-TNFα Therapy: An Alert for Our Patients?. Journal of Crohn's and Colitis, 2016, 10, 1455-1456.	1.3	4
71	Su1072 Air Swallowed During Meals Increases Frequency of Transient LES Relaxations and Trans-Sphincteric Pressure Gradient in NERD Patients and Healthy Controls. Gastroenterology, 2016, 150, S459.	1.3	0
72	Gut Microbiota Dysbiosis as Risk and Premorbid Factors of IBD and IBS Along the Childhood–Adulthood Transition. Inflammatory Bowel Diseases, 2016, 22, 487-504.	1.9	117

#	Article	IF	Citations
73	Sa1452 Impact of Weight Loss on Surgical Outcomes in Resectable Pancreatic Cancer Patients Undergoing Pancreaticoduodenectomy (PD). Gastroenterology, 2016, 150, S319.	1.3	О
74	Tu1851 Protective Effect of Inulin on LPS-Induced Intestinal Smooth Muscle Impairment: A Proteomic Approach. Gastroenterology, 2016, 150, S960.	1.3	0
75	Su1073 Relation Between Distal Contractile Integral, Acid Exposure Time and Bolus Transit in Patients With Non-Obstructive Dysphagia. Gastroenterology, 2016, 150, S459-S460.	1.3	0
76	Sullos Extent of Esophageal Shortening Is Greater in Incomplete Transient LES Relaxations Than Swallows in NERD Patients and Healthy Controls. Gastroenterology, 2016, 150, S471.	1.3	2
77	Intra-bolus pressure and esophagogastric gradient, assessed with high-resolution manometry, are associated with acid exposure and proximal migration of refluxate. Ecological Management and Restoration, 2016, 29, 1020-1026.	0.4	8
78	Randomised controlled trial of mesalazine in IBS. Gut, 2016, 65, 82-90.	12.1	91
79	Gastrointestinal neuromuscular apparatus: An underestimated target of gut microbiota. World Journal of Gastroenterology, 2016, 22, 9871.	3.3	24
80	Eosinophilic esophagitis: New insights in pathogenesis and therapy. World Journal of Gastrointestinal Pharmacology and Therapeutics, 2016, 7, 66.	1.1	16
81	Tu1434 Duodenal Acid Perfusion in Healthy Volunteers Alters Proximal Gastric Motor Function Resulting in Impaired Gastric Accommodation and Reduced Food Intake. Gastroenterology, 2015, 148, S-890.	1.3	1
82	Mo1113 Relevance of Mixed Reflux and Weak Peristalsis With Delayed Reflux Clearance in Chest Pain Perception in NERD Patients. Gastroenterology, 2015, 148, S-609.	1.3	0
83	505 Impaired Esophageal Mucosa Integrity in Refractory Reflux Disease Patients on Proton Pump Inhibitors. A Role for Residual Acid Reflux?. Gastroenterology, 2015, 148, S-99.	1.3	1
84	Mo1114 Increased Frequency of Swallows During 24 Hours in NERD Non Responders to Proton Pump Inhibitors. Gastroenterology, 2015, 148, S-610.	1.3	0
85	Mo1915 Analysis of Solid Swallows At High Resolution Manometry Unmasks Impaired Peristalsis in NERD Patients With Delayed Reflux Clearance. Gastroenterology, 2015, 148, S-738.	1.3	0
86	Su2050 Supernatants of Mucosal Biopsies From Irritable Bowel Syndrome Patients Impair Human Colonic Smooth Muscle Contractility. Gastroenterology, 2015, 148, S-585.	1.3	0
87	Reply. Gastroenterology, 2015, 148, 1067.	1.3	0
88	Confirmatory factor analysis of the Patient Assessment of Constipation-Symptoms (PAC-SYM) among patients with chronic constipation. Quality of Life Research, 2015, 24, 1597-1605.	3.1	35
89	Antioxidant Activity of Inulin and Its Role in the Prevention of Human Colonic Muscle Cell Impairment Induced by Lipopolysaccharide Mucosal Exposure. PLoS ONE, 2014, 9, e98031.	2.5	66
90	Experimental evidence and mathematical modeling of thermal effects on human colonic smooth muscle contractility. American Journal of Physiology - Renal Physiology, 2014, 307, G77-G88.	3.4	11

#	Article	IF	CITATIONS
91	Acid reflux episodes sensitize the esophagus to perception of weakly acidic and mixed reflux in nonâ€erosive reflux disease patients. Neurogastroenterology and Motility, 2014, 26, 108-114.	3.0	15
92	Impedance-High Resolution Manometry Analysis of Patients With Nonerosive Reflux Disease. Clinical Gastroenterology and Hepatology, 2014, 12, 52-57.	4.4	27
93	Reflux pattern and role of impedanceâ€pH variables in predicting PPI response in patients with suspected GERDâ€related chronic cough. Alimentary Pharmacology and Therapeutics, 2014, 40, 966-973.	3.7	63
94	Dilated intercellular space diameter as marker of refluxâ€related mucosal injury in children with chronic cough and gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2014, 39, 733-742.	3.7	13
95	Weak Peristalsis With Large Breaks Is Associated With Higher Acid Exposure and Delayed Reflux Clearance in the Supine Position in GERD Patients. American Journal of Gastroenterology, 2014, 109, 46-51.	0.4	85
96	White Paper of Italian Gastroenterology: Delivery of services for digestive diseases in Italy: Weaknesses and strengths. Digestive and Liver Disease, 2014, 46, 579-589.	0.9	40
97	<i><scp>L</scp>actobacillus rhamnosus</i> protects human colonic muscle from pathogen lipopolysaccharideâ€induced damage. Neurogastroenterology and Motility, 2013, 25, 984.	3.0	31
98	Gastrointestinal sensitivity and gastroesophageal reflux disease. Annals of the New York Academy of Sciences, 2013, 1300, 80-95.	3.8	12
99	Adalimumab in active ulcerative colitis: A "real-life―observational study. Digestive and Liver Disease, 2013, 45, 738-743.	0.9	72
100	Human colonic myogenic dysfunction induced by mucosal lipopolysaccharide translocation and oxidative stress. Digestive and Liver Disease, 2013, 45, 1011-1016.	0.9	12
101	A survey of pharmacological and nonpharmacological treatment of functional gastrointestinal disorders. United European Gastroenterology Journal, 2013, 1, 385-393.	3.8	62
102	Ursodeoxycholic acid therapy in gallbladder disease, a story not yet completed. World Journal of Gastroenterology, 2013, 19, 5029.	3.3	77
103	Gastro-esophageal reflux disease and obesity, where is the link?. World Journal of Gastroenterology, 2013, 19, 6536.	3.3	45
104	Gastroesophageal reflux disease: Update on inflammation and symptom perception. World Journal of Gastroenterology, 2013, 19, 6523.	3.3	64
105	Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World Journal of Gastroenterology, 2013, 19, 6529.	3.3	64
106	Impedance baseline and reflux perception in responder and non-responder non-erosive reflux disease patients. Scandinavian Journal of Gastroenterology, 2012, 47, 1266-1273.	1.5	32
107	Baseline Impedance Levels and Structural and Functional Integrity of the Esophageal Mucosa: Is Acid Still the Only Player?. American Journal of Gastroenterology, 2012, 107, 1104.	0.4	5
108	HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells. American Journal of Physiology - Renal Physiology, 2012, 303, G635-G645.	3.4	46

#	Article	IF	Citations
109	Increased frequency and enhanced perception of reflux in non-erosive reflux disease patients non-responders to proton pump inhibitors. Digestive and Liver Disease, 2012, 44, 549-554.	0.9	30
110	Oesophageal mucosal intercellular space diameter and reflux pattern in childhood erosive and non-erosive reflux disease. Digestive and Liver Disease, 2012, 44, 981-987.	0.9	13
111	Upper Gastrointestinal Involvement of Crohn's Disease: A Prospective Study on the Role of Upper Endoscopy in the Diagnostic Work-Up. Digestive Diseases and Sciences, 2012, 57, 1618-1623.	2.3	120
112	Relationship between baseline impedance levels and esophageal mucosal integrity in children with erosive and nonâ€erosive reflux disease. Neurogastroenterology and Motility, 2012, 24, 828.	3.0	53
113	Plateletâ€activating factor and distinct chemokines are elevated in mucosal biopsies of erosive compared with nonâ€erosive reflux disease patients and controls. Neurogastroenterology and Motility, 2012, 24, 943.	3.0	22
114	Progesterone receptors and serotonin levels in colon epithelial cells from females with slow transit constipation. Neurogastroenterology and Motility, 2011, 23, 575-e210.	3.0	32
115	Measurement of acid exposure of proximal esophagus: a better tool for diagnosing non-erosive reflux disease. Neurogastroenterology and Motility, 2011, 23, 711-e324.	3.0	1
116	Barrett's esophagus: clinical features, obesity, and imaging. Annals of the New York Academy of Sciences, 2011, 1232, 36-52.	3.8	4
117	Esophageal disease: updated information on inflammation. Annals of the New York Academy of Sciences, 2011, 1232, 369-375.	3.8	9
118	Effect of ursodeoxycholic acid on inflammatory infiltrate in gallbladder muscle of cholesterol gallstone patients. Neurogastroenterology and Motility, 2010, 22, 866.	3.0	26
119	Increased TRPV1 gene expression in esophageal mucosa of patients with non-erosive and erosive reflux disease. Neurogastroenterology and Motility, 2010, 22, 746-e219.	3.0	107
120	Spondyloarthropathy associated with Crohn's disease treated with adalimumab. Digestive and Liver Disease Supplements, 2010, 4, 4-6.	0.2	0
121	Diagnosis and Management of Non-Erosive Reflux Disease – The Vevey NERD Consensus Group. Digestion, 2009, 80, 74-88.	2.3	131
122	Regional oesophageal sensitivity to acid and weakly acidic reflux in patients with nonâ€erosive reflux disease. Neurogastroenterology and Motility, 2009, 21, 253-258.	3.0	46
123	Proximal oesophagus: the added value in understanding GORD symptoms. Neurogastroenterology and Motility, 2009, 21, 790-795.	3.0	14
124	Intercellular space diameters of the oesophageal epithelium in NERD patients: Head to head comparison between light and electron microscopy analysis. Digestive and Liver Disease, 2009, 41, 9-14.	0.9	28
125	Maintenance treatment with infliximab for the management of Crohn's disease in adults. Biologics: Targets and Therapy, 2009, 3, 39-49.	3.2	6
126	Dynamic contrast enhanced magnetic resonance imaging of the terminal ileum: differentiation of activity of Crohn's disease. Abdominal Imaging, 2008, 33, 417-424.	2.0	114

#	Article	IF	Citations
127	Impaired contractility of colonic muscle cells in a patient with chronic intestinal pseudo-obstruction. Digestive and Liver Disease, 2008, 40, 225-229.	0.9	5
128	Long-term treatment with infliximab in inflammatory bowel disease: safety and tolerability issues. Expert Opinion on Drug Safety, 2008, 7, 617-632.	2.4	39
129	Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut, 2008, 57, 1740-1741.	12.1	15
130	Effect of Acute Mucosal Exposure to Lactobacillus rhamnosus GG on Human Colonic Smooth Muscle Cells. Journal of Clinical Gastroenterology, 2008, 42, S185-S190.	2.2	36
131	Ursodeoxycholic acid improves muscle contractility and inflammation in symptomatic gallbladders with cholesterol gallstones. Gut, 2007, 56, 815-820.	12.1	53
132	Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut, 2007, 57, 443-447.	12.1	100
133	Effect of oesophagitis on proximal extent of gastro-oesophageal reflux. Neurogastroenterology and Motility, 2007, 19, 459-464.	3.0	15
134	Dilated intercellular spaces and acid reflux at the distal and proximal oesophagus in patients with nonâ€erosive gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2007, 25, 629-636.	3.7	107
135	Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up. World Journal of Gastroenterology, 2007, 13, 5238.	3.3	52
136	Associations between the IGF system and inflammatory markers in inflammatory bowel disease: authors' reply. Alimentary Pharmacology and Therapeutics, 2006, 23, 554-555.	3.7	2
137	Effect of hiatal hernia on proximal oesophageal acid clearance in gastro-oesophageal reflux disease patients. Alimentary Pharmacology and Therapeutics, 2006, 23, 751-757.	3.7	46
138	Immunohistochemical evaluation of pRb2/p130, VEGF, EZH2, p53, p16, p21waf-1, p27, and PCNA in Barrett's esophagus. Journal of Cellular Physiology, 2006, 207, 512-519.	4.1	29
139	Short-term ursodeoxycholic acid treatment improves gallbladder bile turnover in gallstone patients: a randomized trial. Neurogastroenterology and Motility, 2005, 17, 680-686.	3.0	10
140	Infliximab reverses growth hormone resistance associated with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2005, 21, 1063-1071.	3.7	48
141	Effect of endoscopic augmentation of the lower oesophageal sphincter (Gatekeeper reflux repair) Tj ETQq $1\ 1\ 0.7$	84314 rgt 12.1	BT /Overlock
142	Dilated Intercellular Spaces of Esophageal Epithelium in Nonerosive Reflux Disease Patients with Physiological Esophageal Acid Exposure. American Journal of Gastroenterology, 2005, 100, 543-548.	0.4	221
143	Gatekeeper TM Reflux Repair System: Results of Two Years Follow-up. Gastrointestinal Endoscopy, 2004, 59, P244.	1.0	2
144	Intraâ€oesophageal distribution and perception of acid reflux in patients with nonâ€erosive gastroâ€oesophageal reflux disease. Alimentary Pharmacology and Therapeutics, 2003, 18, 605-613.	3.7	140

#	Article	IF	CITATIONS
145	Scintigraphic assessment of SO dysfunction. Gut, 2003, 52, 1655-1656.	12.1	17
146	Outcome of endoscopic sphincterotomy in post cholecystectomy patients with sphincter of Oddi dysfunction as predicted by manometry and quantitative choledochoscintigraphy. Gut, 2002, 50, 665-668.	12.1	71
147	Endoscopic implantation of a biopolymer in the lower esophageal sphincter for gastroesophageal reflux: A pilot study. Gastrointestinal Endoscopy, 2002, 55, 335-341.	1.0	115
148	Ultrasonographic assessment of gallbladder bile exchanges in healthy subjects and in gallstone patients. Ultrasound in Medicine and Biology, 2001, 27, 1445-1450.	1.5	9
149	Increased sphincter of Oddi basal pressure in patients affected by gall stone disease: a role for biliary stasis and colicky pain?. Gut, 2001, 48, 414-417.	12.1	25
150	Antro-pyloric contractile patterns and transpyloric flow after meal ingestion in humans. American Journal of Gastroenterology, 1998, 93, 2513-2522.	0.4	48
151	Effect of endogenous cholecystokinin on postprandial gallbladder refilling. Digestive Diseases and Sciences, 1995, 40, 76-81.	2.3	10
152	Gallbladder Emptying during High-Dose Cholecystokinin Infusions Effect in Patients with Gallstone Disease and Healthy Controls. Scandinavian Journal of Gastroenterology, 1995, 30, 128-132.	1.5	4
153	Hepatoduodenal bile transit in cholecystectomized subjects. Digestive Diseases and Sciences, 1994, 39, 1985-1993.	2.3	61
154	Correlation between gall bladder fasting volume and postprandial emptying in patients with gall stones and healthy controls Gut, 1993, 34, 1443-1447.	12.1	48
155	Quantitative cholescintigraphy in the assessment of choledochoduodenal bile flow. Gastroenterology, 1991, 100, 1106-1113.	1.3	49